Beijing AI+Blockchain Pharma Startup Received Millions of USD Pre-A Financing

Deep Intelligent Pharma (DIP), a company integrating artificial intelligent (AI) technology with pharmaceutical development, received millions of US dollar from ZhenFund, a Beijing-based seed capital, in its pre-A round financing last December. This message was released by a spokesperson at DIP on May 24.

By Joanne Shih

DIP is a technology start-up launched in Beijing in October 2017, applying AI and blockchain technologies to facilitate drug discovery, development, and medical regulatory affairs. Established in China, the company sets its headquarters in Beijing, but branches in both China and the US with offices in Shanghai, Shenyang, Boston, and Silicon Vally. Currently, DIP has over 50 full-time employees.

The company has launched around ten products and collaborated with several Chinese, Asia Pacific, and global pharmaceutical companies since its establishment. Aiming to empower advancement in medical and pharmaceutical industries, DIP has six major product lines which respectively are: 1) Intelligent Pharmacovigilance, 2) A.I.M AI IN MEDICAL, 3) A Blockchain-based, Patient-research Ecosystem, 4) Intelligent Medical Writing, 5) Medical Translations, and 6) Intelligent Regulatory Affairs Solution. Among these products, AI and blockchain play a pivot role in creating new platforms for medical and clinical research and in allowing medical data to be used appropriately.

Emma Yin, Investment Vice President at ZhenFund, said, “DIP is formed by a talented pool from international pharmaceutical giants including Johnson & Johnson, Pfizer, Eli Lilly, Novartis, as well as AI algorithmists from Alibaba and experts in natural language processing. It is a true combination of AI technology and drug R&D. Therefore, DIP has the potential to develop viable solutions and meet demands in pharmaceutical market.”

Reference

https://ibmi.taiwan-healthcare.org/news_detail.php?REFDOCTYPID=&REFDOCID=0p99g009btfcwvn

Related posts:

AI Powered Startup XtalPi Announces 300 Million Series C Funding Data-Driven Molecular Engineering Startup Partners with Takeda to Develop Next-Gen Gene Therapies Israeli Startup Raises $40 Million in Series B to Develop Cures for Food Allergies Ultima Genomics Promises $100 Genome After Raising $600 Million

Author

GeneOnline